An indirect comparison of 144-week efficacy, safety, and tolerability of dolutegravir plus lamivudine and second-generation integrase inhibitor–based, 3-drug, single-tablet regimen... by Lee A. Evitt, Sakina Nanji, Richard A. Grove, Chinyere Okoli, Jean van Wyk, Sonya J. Snedecor

Get full text

Dual Therapy Treatment Strategies for the Management of Patients Infected with HIV: A Systematic Review of Current Evidence in ARV-Naive or ARV-Experienced, Virologically Suppresse... by Jean-Guy Baril, Jonathan B Angel, M John Gill, Joseph Gathe, Pedro Cahn, Jean van Wyk, Sharon Walmsley

Get full text

Dolutegravir-based regimens in treatment-naive and treatment-experienced aging populations: analyses of 6 phase III clinical trials by Frank Spinelli, Manyu Prakash, Jill Slater, Mike van der Kolk, Niccolò Bassani, Richard Grove, Brian Wynne, Jean van Wyk, Andrew Clark

Get full text

MUDANÇA PARA DTG/3TC EM COMBINAÇÃO DE DOSE FIXA FOI NÃO‐INFERIOR À CONTINUIDADE DE ESQUEMA BASEADO EM TAF (TBR) NA MANUTENÇÃO DA SUPRESSÃO VIRAL POR 96 SEMANAS (ESTUDO TANGO)... by Jean Van Wyk, Faïza Ajana, Fiona Bisshop, Stéphane de Wit, Mounir Ait‐Khaled, Ruolan Wang, Jonathan Wright, Michael Aboud, Kimberly Smith, Roberto Zajdenverg

Get full text

Predictors of RSV LRTI Hospitalization in Infants Born at 33 to 35 Weeks Gestational Age: A Large Multinational Study (PONI). by Zbyněk Straňák, Elie Saliba, Paraskevi Kosma, Klara Posfay-Barbe, Khalid Yunis, Teresa Farstad, Kristina Unnebrink, Jean van Wyk, Colleen Wegzyn, Gerard Notario, Stefanie Kalus, Fiona J Campbell

Get full text

Impact of treatment adherence on efficacy of dolutegravir plus lamivudine and dolutegravir plus tenofovir disoproxil fumarate/emtricitabine: pooled analysis of the GEMINI-1 and GEM... by Mounir Ait-Khaled, Juan Sierra Madero, Vicente Estrada, Roberto Gulminetti, Debbie Hagins, Hung-Chin Tsai, Choy Man, Jörg Sievers, Richard Grove, Andrew Zolopa, Brian Wynne, Jean van Wyk

Get full text

Cabotegravir + Rilpivirine Long-Acting Injections for HIV Treatment in the US: Real World Data from the OPERA Cohort by Michael G. Sension, Laurence Brunet, Ricky K. Hsu, Jennifer S. Fusco, Quateka Cochran, Christine Uranaka, Gayathri Sridhar, Vani Vannappagari, Jean Van Wyk, Lewis McCurdy, Michael B. Wohlfeiler, Gregory P. Fusco

Get full text

Assessing the Virologic Impact of Archived Resistance in the Dolutegravir/Lamivudine 2-Drug Regimen HIV-1 Switch Study TANGO through Week 144 by Ruolan Wang, Jonathan Wright, Parminder Saggu, Mounir Ait-Khaled, Riya Moodley, Chris M. Parry, Thomas Lutz, Daniel Podzamczer, Richard Moore, Miguel Górgolas Hernández-Mora, Clifford Kinder, Brian Wynne, Jean van Wyk, Mark Underwood

Get full text

Practical dosing guidance for the management of clinician-administered injections of long-acting cabotegravir and rilpivirine by Parul Patel, Paula Teichner, Emilie Elliot, Marta Boffito, Milena Murray, Joseph W. Polli, Mark Baker, Susan L. Ford, Kelong Han, Alberto Russu, Herta Crauwels, Ronald D. D’Amico, William R. Spreen, Jean van Wyk

Get full text

TROCA PARA UM REGIME COM 2 MEDICAMENTOS DOLUTEGRAVIR / LAMIVUDINA (DTG / 3TC) EM DOSE FIXA COMBINADA É NÃO INFERIOR A CONTINUAR COM UM REGIME DE 3 MEDICAMENTOS POR 48 SEMANAS EM UM... by Josep M. Llibre, Carlos Brites, Chien-yu Cheng, Olayemi Osiyemi, Carlos Galera, Laurent Hocqueloux, Franco Maggiolo, Olaf Degen, Libby Blair, Brian Wynne, James Oyee, Mark Underwood, Lloyd Curtis, Gilda Bontempo, Jean van Wyk, Jucival Fernandes

Get full text

TROCA PARA A COMBINAÇÃO DE DOSE FIXA DE DOLUTEGRAVIR/LAMIVUDINA É NÃO INFERIOR A UM REGIME BASEADO EM TENOFOVIR ALAFENAMIDA NA MANUTENÇÃO DA SUPRESSÃO VIROLÓGICA POR 144 SEMANAS (E... by Olayemi Osiyemi, Faïza Ajana, Fiona Bisshop, Stéphane de Wit, Joaquín Portilla, Jean-pierre Routy, Christoph Wyen, Mounir Ait-khaled, Keith A. Pappa, Ruolan Wang, Peter A. Leone, Jonathan Wright, Brian Wynne, Jean van Wyk, Michael Aboud, Kimberly Y. Smith

Get full text